Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study

• Published in: Prostate international Vol. 4; no. 4; pp. 140 - 144
• Main Authors: Kandori, Shuya, Yoshino, Takayuki, Tsutsumi, Masakazu, Yamauchi, Atsushi, Ohtani, Mikinobu, Fukuhara, Yoshiharu, Miyanaga, Naoto, Miyazaki, Jun, Nishiyama, Hiroyuki, Shimazui, Toru
• Format: Journal Article
• Language: English
• Published: Korea (South) Elsevier B.V 01.12.2016; Asian Pacific Prostate Society; Elsevier
• Subjects: Castration-resistant prostate cancer; Cause-specific survival; Docetaxel; Original; Secondary hormonal therapies; Castration-resistant prostate cancer; Secondary hormonal therapies; Cause-specific survival; Docetaxel
• ISSN: 2287-8882; 2287-903X
• DOI: 10.1016/j.prnil.2016.09.001

We retrospectively analyzed castration-resistant prostate cancer (CRPC) patients treated with secondary hormonal therapies (SHTs) prior to docetaxel therapy. The cases of 73 CRPC patients who underwent docetaxel therapy in 2005–2011 at four hospitals in Ibaraki, Japan were analyzed. We determined the cause-specific survival (CSS) from the start of docetaxel therapy and the time point of CRPC diagnosis, and we compared the CSS achieved with/without prior classical SHTs, which were defined as low-dose steroid and estramustine phosphate. Of the 73 enrolled patients, 26 underwent docetaxel therapy (DOC group), and 47 underwent SHTs (SHTs-DOC group) as the initial treatment for CRPC. In the docetaxel therapy, the rate of prostate-specific antigen responses were higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%, P = 0.0066). The median CSS from the docetaxel therapy initiation was not significant but longer in the DOC group than in the SHTs-DOC group (23.4 months vs. 16.6 months, P = 0.0969). However, the median CSS from the time of CRPC diagnosis did not significantly differ between the DOC and SHTs-DOC groups (23.4 months vs. 24.7 months, P = 0.9233). In a univariate analysis, pain and visceral metastasis appeared to be risk factors for the CSS in the SHTs-DOC group. The patients with pain and/or visceral metastasis had significantly poorer survival than those without these factors in the SHTs-DOC group (31.5 months vs. 16.8 months, P = 0.0053). The induction of SHTs prior to docetaxel therapy is an acceptable treatment option with some survival benefits for CRPC patients without pain and visceral metastases.